Pre-NDA Meetings Slated For Overhaul As Part Of New User Fee Cycle
Executive Summary
BOSTON - The renewal of the user fee program will produce significant changes in how FDA and application sponsors approach their presubmission meetings, Office of New Drugs Deputy Director Sandra Kweder said